Sinovac Reports First Half 2007 Financial Results
First Half 2007 Highlights -- Sales increased 189% year-over-year to $13.5 million -- Gross profit grew 210% year-over-year to $11.6 million -- Operating income rose to US$6.1 million, up from an operating loss of $660,000 in same period 2006 -- Net in...
Sinovac Commences Vaccination of Volunteers for the Clinical Research of Pandemic Influenza Vaccine (H5N1)
BEIJING, Aug. 14 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a China-based biopharmaceutical company focusing on vaccine development, today announced that it has commenced vaccination of volunteers for the clinical research of Pandemic Influenza Vaccine (H5N1), which is the continue...
Sinovac Schedules First Half 2007 Financial Results Date
BEIJING, Aug. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release financial results for the six months ended June 30, 2007 before the market opens on Thursday, August 16, 2007 with an acco...
Sinovac Enters Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd.
BEIJING, Aug. 1 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced it has entered into an Exclusive Promotion Service Agreement with GlaxoSmithKline (China) Investment Co., Ltd. (or "GSK China"). GSK China and Sinov...
Sinovac Schedules Annual General Meeting
BEIJING, July 31 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its Annual General Meeting on Tuesday, August 21, 2007 at 9:00 a.m. Bejing Time. The meeting will be held concurrently at No....
Sinovac Receives Full Payment for Heping Wang’s Obligations
BEIJING, July 27 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a China-based vaccine company, announced today that it has received full payment of Heping Wang’s outstanding obligations to Sinovac. In connection with the repayment, Sinovac has agreed to the release from escrow 1.5 mil...
Sinovac Issues Corporate Update
BEIJING, June 2 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a vaccine-focused biotech company in China, today issued a corporate update. As previously disclosed in Sinovac’s annual report on Form 20-F, Heping Wang, a former director, owed Sinovac outstanding obligations in the...
Sinovac Commences Phase II Clinical Trials for Pandemic Influenza Vaccine (H5N1)
BEIJING, May 9 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced that the China State Food and Drug Administration (SFDA) recently granted Sinovac approval to commence the Phase II clinical trial of Panflu(TM), a...
Sinovac to Present at 2007 UBS Global Generic and Specialty Pharmaceuticals Conference
BEIJING, April 30 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that it has scheduled to present at the 2007 UBS Global Generic and Specialty Pharmaceuticals Conference on Tuesday, May 8, 2007. Weidong Yin, ...
Sinovac Reports 2006 Financial Results
BEIJING, April 12 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced audited financial results for the year ended December 31, 2006. 2006 Highlights -- Sales increased 78.4% year over year to US$15....
Sinovac Reports First Quarter 2007 Unaudited Sales
BEIJING, April 12 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced unaudited sales revenue for the first quarter ended March 31, 2007. Unaudited sales for the first quarter 2007 rose 134% to RMB 30.57 mill...
Sinovac Schedules 2006 Financial Results Date
BEIJING, April 9 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release financial results for the twelve months ended December 31, 2006 before the market opens on Thursday, April 12, 2007 with an ...
Sinovac Provides Update on Study of Third Dose of Its Pandemic Influenza Vaccine
BEIJING, March 6 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced an update for the study evaluating the third dose of its vaccine against the H5N1 dose of pandemic influenza. In order to test the immune...
Sinovac Attended 3rd WHO Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials
BEIJING, Feb. 20 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced that Sinovac attended the 3rd WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials. The meeting was held on Feb...
Sinovac Files Registration Documents for Euvax-B(TM) with SFDA Loan Repayment Received from One Former Director
BEIJING, Feb. 8 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of biopharmaceutical products in China, today announced it has filed registration documents with the China State Food and Drug Administration for LG Life Sciences (LGLS) hepatitis B vaccine, Euvax-B(TM)...
